May 8 (Reuters) - Viatris Inc VTRS.O:
VIATRIS ANNOUNCES POSITIVE RESULTS FROM PHASE 3 STUDY OF INVESTIGATIONAL XULANE LO™ LOW DOSE PATCH FOR BIRTH CONTROL IN WOMEN OF CHILDBEARING POTENTIAL
VIATRIS INC - NDA SUBMISSION TO FDA EXPECTED IN SECOND HALF OF 2025
VIATRIS INC - FAVORABLE SAFETY PROFILE WITH MILD-TO-MODERATE ADVERSE EVENTS
VIATRIS INC - XULANE LO ACHIEVES PRIMARY AND SECONDARY EFFICACY AND SAFETY ENDPOINTS
Source text: ID:nPnc7nQRYa
Further company coverage: VTRS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.